LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

United Therapeutics Corp

Geschlossen

BrancheGesundheitswesen

400.72 5.52

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

396.58

Max

400.72

Schlüsselkennzahlen

By Trading Economics

Einkommen

-13M

310M

Verkäufe

4.2M

799M

KGV

Branchendurchschnitt

15.794

35.733

EPS

6.63

Gewinnspanne

38.755

Angestellte

1,305

EBITDA

54M

437M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+16.24% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

4.9B

18B

Vorheriger Eröffnungskurs

395.2

Vorheriger Schlusskurs

400.72

Nachrichtenstimmung

By Acuity

32%

68%

98 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

United Therapeutics Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Okt. 2024, 15:14 UTC

Wichtige Markttreiber

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28. Jan. 2025, 10:30 UTC

Top News

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Peer-Vergleich

Kursveränderung

United Therapeutics Corp Prognose

Kursziel

By TipRanks

16.24% Vorteil

12-Monats-Prognose

Durchschnitt 465.56 USD  16.24%

Hoch 575 USD

Tief 295 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für United Therapeutics Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

8

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

292.345 / 309.245Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

98 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat